Insider Selling: Santarus VP Unloads 15,165 Shares of Stock (SNTS)
Santarus (NASDAQ:SNTS) VP Meules Julie De sold 15,165 shares of the stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $21.14, for a total value of $320,588.10. Following the completion of the sale, the vice president now directly owns 380 shares in the company, valued at approximately $8,033. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Santarus (NASDAQ:SNTS) traded up 2.81% on Thursday, hitting $21.92. 1,397,430 shares of the company’s stock traded hands. Santarus has a 1-year low of $8.47 and a 1-year high of $28.10. The stock’s 50-day moving average is $22.5 and its 200-day moving average is $21.81. The company has a market cap of $1.455 billion and a price-to-earnings ratio of 14.86.
Santarus (NASDAQ:SNTS) last released its earnings data on Tuesday, August 6th. The company reported $0.94 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.18 by $0.76. The company had revenue of $89.40 million for the quarter, compared to the consensus estimate of $82.90 million. During the same quarter in the prior year, the company posted $0.05 earnings per share. The company’s quarterly revenue was up 89.4% on a year-over-year basis. On average, analysts predict that Santarus will post $1.26 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on SNTS shares. Analysts at Ned Davis Research initiated coverage on shares of Santarus in a research note to investors on Monday. They set a “neutral” rating on the stock. Separately, analysts at Leerink Swann downgraded shares of Santarus from an “outperform” rating to a “market perform” rating in a research note to investors on Thursday, August 22nd. They now have a $26.00 price target on the stock. They noted that the move was a valuation call. Finally, analysts at JMP Securities raised their price target on shares of Santarus from $27.00 to $31.00 in a research note to investors on Wednesday, August 7th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $25.63.
Santarus, Inc (NASDAQ:SNTS) is a specialty biopharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by physician specialists.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.